New forecasting technique 'set to move pharma to new areas'

It's set to turn business intelligence on its head. One senior pharma director of strategic planning has announced it 'will move pharma to new areas'. It's a new forecasting technology that's already been adopted by Novartis, GSK, Lilly, J&J and Pfizer. It's called 'A Prediction Market'.

There are three places you can find out more about Prediction Markets and pharma:

  • Free Exclusive Eyeforpharma Podcast which includes the highlights of a recent exclusive conference speech and an interview with the world academic expert all in just 10-minutes!
  • A Free White Paper on the subject, which includes a concise explanation, statistics and quotes
  • A highly informative live 1-hour online conference on Wednesday 5th September for only $99 if you book this week (reduced from $199). Learn from the experts - you'll hear 3 world class authorities addressing the subject.

More information and all 3 sources can be accessed at www.eyeforpharma.com/virtual/forecastingpm/

About EyeforPharma
EyeforPharma is a global pharmaceutical business strategy information provider with a highly reputable and worldwide presence in the pharma industry. It is renowned for producing top level conferences that attract the highest level of speakers to deliver presentations on cutting edge pharmaceutical business strategies. It provides business intelligence and analysis online at www.eyeforpharma.com. EyeforPharma also has a very strong foothold in the European, US and Japanese markets.

Most Popular Now

SK bioscience and GSK start Phase 3 trial of adjuv…

SK bioscience (SK) and GlaxoSmithKline plc (GSK) today announced the initiation of a Phase 3 clinical study of SK's COVID-19 vaccine candidate, GBP510, in combination wit...

No serious health effects linked to mRNA COVID-19 …

Federal and Kaiser Permanente researchers combing the health records of 6.2 million patients found no serious health effects that could be linked to the 2 mRNA COVID-19 v...

Blood vessels produce growth factor that promotes …

Blood vessels supply tumors with nutrients and, on the other hand, enable cancer cells to spread throughout the body. The settlement of circulating tumor cells in a dista...

First-in-human clinical trial for a vaccine to tre…

The first patients have been enrolled in a phase 1 randomized placebo-controlled clinical trial to study a therapeutic vaccine for opioid use disorder developed by resear...

Sandoz strengthens pipeline by entering into agree…

Sandoz, a Novartis division, today announced that it has entered into a commercialization agreement with Bio-Thera Solutions, Ltd. for biosimilar bevacizumab (BAT1706). B...

Pfizer and BioNTech submit a variation to EMA with…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that they submitted a variation to the European Medicines Agency (EMA) requesting to update the Condition...

A drug costing less than €2 a day helps in the tre…

Metoprolol, a drug widely used to treat cardiovascular disease, is beneficial when administered to COVID-19patients. This is the finding of a study by investigators at th...

Rheumatoid arthritis treated with implanted cells …

With a goal of developing rheumatoid arthritis therapies with minimal side effects, researchers at Washington University School of Medicine in St. Louis have genetically ...

NIH scientists build a cellular blueprint of multi…

Chronic lesions with inflamed rims, or "smoldering" plaques, in the brains of people with multiple sclerosis (MS) have been linked to more aggressive and disabling forms ...

Scientific evidence to date on COVID-19 vaccine ef…

An expert review by an international group of scientists, including some at the WHO and FDA, concludes that, even for the delta variant, vaccine efficacy against severe C...

How a plant virus could protect and save your lung…

Using a virus that grows in black-eyed pea plants, nanoengineers at the University of California San Diego developed a new treatment that could keep metastatic cancers at...

COVID-19 nasal vaccine candidate effective at prev…

Breathe in, breathe out. That’s how easy it is for SARS-CoV-2, the virus that causes COVID-19, to enter your nose. And though remarkable progress has been made in develop...